Company / R&D Expense
AVADEL PHARMACEUTICALS PLC R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$15.2M
FY2024
5-year range
$13.3M / $20.7M
FY2020-FY2024
Trend
+14.6%
vs FY2023
Sector context
#201 of 210
Health Care
What the data says
Among 210 Health Care companies, AVADEL PHARMACEUTICALS PLC is in the bottom 4% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $13M in FY2023 to $39M in FY2018.
Based on SEC 10-K filings.
$15M in FY2024 with a 5-year CAGR of -14.3%.
Declined from $21M to $15M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -3.9%
- 5-Year CAGR
- -14.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 210This company $15.2M Sector average $644.1M
▼
-97.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -14.3%, indicating a declining trend.
- In FY2024, r&d expense increased 14.6% year-over-year.
- Ranks #201 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $15.2M | +14.6% |
| FY2023 | $13.3M | -35.9% |
| FY2022 | $20.7M | +21.0% |
| FY2021 | $17.1M | -16.3% |
| FY2020 | $20.4M | -37.9% |
| FY2019 | $32.9M | -16.3% |
| FY2018 | $39.3M | +17.7% |
| FY2017 | $33.4M | -3.4% |
| FY2016 | $34.6M | +35.2% |
| FY2015 | $25.6M | +48.0% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026